TD Cowen lowered shares of Aadi Bioscience (NASDAQ:AADI – Free Report) from a buy rating to a hold rating in a research report sent to investors on Wednesday, MarketBeat reports.
Separately, HC Wainwright reaffirmed a neutral rating on shares of Aadi Bioscience in a research note on Tuesday, May 14th.
Get Our Latest Stock Analysis on Aadi Bioscience
Aadi Bioscience Trading Up 1.9 %
Aadi Bioscience (NASDAQ:AADI – Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.17. Aadi Bioscience had a negative net margin of 288.72% and a negative return on equity of 61.83%. The firm had revenue of $6.18 million during the quarter, compared to analyst estimates of $6.33 million. During the same quarter last year, the business posted ($0.67) EPS. Research analysts forecast that Aadi Bioscience will post -2.54 EPS for the current fiscal year.
Insider Activity
In other Aadi Bioscience news, Chairman Neil Desai sold 31,348 shares of the business’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $1.45, for a total value of $45,454.60. Following the completion of the sale, the chairman now directly owns 1,260,195 shares of the company’s stock, valued at $1,827,282.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 52,415 shares of company stock worth $76,151 in the last three months. 37.30% of the stock is owned by insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. acquired a new position in Aadi Bioscience during the second quarter valued at approximately $37,000. Marquette Asset Management LLC acquired a new position in Aadi Bioscience during the 1st quarter worth $135,000. Acuitas Investments LLC boosted its holdings in Aadi Bioscience by 10.8% during the second quarter. Acuitas Investments LLC now owns 352,483 shares of the company’s stock valued at $515,000 after acquiring an additional 34,344 shares during the period. Finally, Decheng Capital LLC bought a new position in shares of Aadi Bioscience in the fourth quarter worth about $1,063,000. 52.08% of the stock is owned by institutional investors.
Aadi Bioscience Company Profile
Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.
See Also
- Five stocks we like better than Aadi Bioscience
- How to Invest in the Best Canadian Stocks
- Lumen: Among Top Performers Last Month, Still Has Warning Signs
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Baidu’s Strong Quarter Proves a Smart Pick for Michael Burry
- What is MarketRank™? How to Use it
- Intuit Beats Q4 Earnings: AI, Dividends, and a Growth Strategy
Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.